Dubai: The Ministry of Health and Prevention (MoHAP) has inked, on May 27, an agreement with Novartis Middle East on the provision and recycling of the strategic drug stockpile in severe and emergency situations.

The agreement includes 31 life-saving and emergency drugs. The one-year-agreement aims at strengthening the pharmaceutical security and the appropriate response to emergency cases, with the formation of a joint committee to follow up the agreement implementation.

The signing ceremony was held at MOHAP’s headquarters in the presence of His Excellency Dr. Mohamed Salim Al Olama, the Undersecretary of the Ministry of Health and Prevention.

The agreement was signed by Dr. Abdul Karim Abdullah Al Zarouni, Director of MoHAP’s Emergency, Crisis and Disaster Operations Center, and Dr. Mohamed Ezz El-Din, Country Manager, Novartis.

Also, the agreement was attended by Jihad Al Kaissi, Public Affairs Head, Novartis Middle East, and Ibrahim Aqeel, Director of Government Affairs, Novartis.

Dr. Al Zarouni underlined that the signing of this agreement comes within the context of reinforcing the strategic drug stockpile, in adherence to the Cabinet Resolution No. 39/ 2015.

He added that this agreement will cover the needs of the drug stockpile for one year as per the global storage and recycling standards.

Al Zarouni further said: “The agreement comprises 31 drugs including medications for the treatment of immune system disease, cardiovascular disease, urinary tract, gynecology and obstetrics diseases, endocrine disease, blood and malnutrition disease, bone diseases, neurological disease, respiratory system, and other chronic diseases.

For his part, Dr. Mohamed Ezz El-Din emphasized Novartis’s keenness on the constant cooperation with MoHAP for the benefit of society health, through the provision of the drug stockpile which includes 31 essential drugs with a view to ensuring the provision of drugs in emergency and severe cases.    

-Ends-

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.